USD
GBP 
CNY 
EUR 
INR 
JPY 
MYR 
ZAR 
KRW 
THB 
Novel Targeted Therapeutic Strategies Technologies Around Neurodegenerative Disorders - From Palliative to Future Interventions
23-Aug-2019
Global
Technology Research
D8BB-01-00-00-00
HC03209-GL-TR_23535
At present, only a few therapies are available with relatively low success. Both, the clinical and the scientific communities are critically devoted to develop new therapeutic approaches to treat and diagnose neurodegenerative diseases.
At present days, neurodegenerative diseases represent one of the main causes of death in the industrialized economy. Overall characterized by a loss of neurons in particular regions of the nervous system, the subsequent decline in cognitive and motor function that patients experience in these diseases is associated with nerve cell loss.
The most common denominator among neurodegenerative diseases, in addition to nerve cell loss is inflammation. Although, a series of mutant genes and environmental toxins are related to neurodegenerative disorders, the causal mechanisms remain poorly understood.
Neurodegenerative diseases can be defined as multifactorial debilitating disorders of the nervous system. Overall, neurodegenerative diseases affect approximately 30 million individuals worldwide, according to the World Health Organization (WHO).
Factors Contributing to Neurodegenerative Diseases
The factors contributing to the onset of neurodegenerative diseases are multiple. Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS) diseases are well-established as the consequence of misfolding and dysfunctional trafficking of proteins. However, other factors including mitochondrial dysfunction, oxidative stress, aging, and environmental issues are deeply associated with the onset of neurodegeneration.
Molecular Mechanisms Underlying Neurodegeneration
Although all these factors have been demonstrated to significantly contribute to the etiology of common neurodegenerative diseases, some molecular mechanisms underlying neurodegeneration remain unveiled.
Present efforts are focused on the identification of viable drug targets and biomarkers for early diagnosis of the diseases, in order to develop the best suited therapies.
Some Multifactorial Conditions to Watch
Abnormal protein dynamics
Defective protein degradation and aggregation
Oxidative stress
Free radical formation
Impaired bioenergetics
Mitochondrial dysfunction
Exposure to toxic metals and pesticides
Others
Coverage of Neurodegenerative Diseases Technologies
This research service, ‘Emerging Therapeutics for Neurodegenerative Diseases’, focuses on the leading technology and business trends that are making possible the implementation of cutting-edge innovations that help to face the present and future challenges of the neurodegenerative disease therapeutics sector.
The tendencies depicted in this study will help to drive the sustainability of the neurodegenerative disease therapeutics industry by directly exhibiting the principal challenges faced by leading biopharmaceutical and biotechnology companies to develop new product modalities in an affordable and high performance style, while getting market acceptance and achieving market leadership by translating technology innovation to market competitiveness
The study covers the following topics:
Technology roadmap, trends, capabilities, and applications targeted
Stakeholder activities, influence, industry initiatives, investment environment, and funding support
Regional and global regulation landscape and standardization approaches for tackling challenges
Technology benchmarking for smart decisions
An appendix is included, comprising lists of major industry influencers found in the field.
1.1 Facts and Findings: Neurodegenerative Diseases
1.2 Research Focus: Neurodegenerative Diseases
1.3 Research Scope: Foreseeing Challenges and Solutions
1.4 Analysis Framework: Frost & Sullivan’s Core Value
1.5 Research Methodology
2.1 Neurodegenerative Diseases: Facts and Challenges
2.2 Neurodegenerative Diseases: Multifactorial Onset
2.3 Neurodegenerative Diseases: Concurrent Triggering Factors
2.4 Neurodegenerative Diseases: Emerging Therapies
2.5 Neurodegenerative Diseases: Complementary Therapies
3.1 Therapeutic and Diagnostic Solutions: PROTACs
3.2 Neurodegenerative Therapies: Targeting Protein Ligands
3.3 Therapeutic and Diagnostic Solutions: Peptoids
3.4 Neurodegenerative Therapies: Five Peptoid Approaches
3.5 Neurodegenerative Therapies: Aggregation Inhibitors
3.6 Neurodegenerative Therapies: Cell Signaling Modulators
3.7 Neurodegenerative Therapies: Biomimetic Neuroprotectors
3.8 Neurodegenerative Therapies: Inflammation Regulators
3.9 Neurodegenerative Therapies: Imaging Diagnostics Biomarkers
3.10 Neurodegenerative Therapies: Summary of Peptoid Interventions
3.11 Therapeutic and Diagnostic Solutions: Stem Cell/Gene Therapies
3.12 Neurodegenerative Therapies: Cell Therapy Developments
3.13 Therapeutic and Diagnostic Solutions: Gut Microbiome
3.14 Neurodegenerative Therapies: Gut Microbiome Interventions
3.15 Therapeutic and Diagnostic Solutions: Nanotech, Prodrug, and Codrug
3.16 Therapeutic and Diagnostic Solutions: Cannabidiols
3.17 Neurodegenerative Therapies: Prevention and Management
4.1 Neurodegenerative Preclinical Models: Needs and Complexities
4.2 Neurodegenerative Models’ Pitfalls: Alzheimer’s Disease
4.3 Neurodegenerative Models’ Pitfalls: Parkinson’s Disease
4.4 Present Status of Therapeutics Technology
4.5 Alzheimer’s Disease Drug Development Status
4.5 Alzheimer’s Disease Drug Development Status (continued)
4.5 Alzheimer’s Disease Drug Development Status (continued)
4.5 Alzheimer’s Disease Drug Development Status (continued)
4.5 Alzheimer’s Disease Drug Development Status (continued)
4.6 Parkinson’s Disease Drug Development Status
5.1 From Palliative Treatment to Future Strategies
5.2 New Treatment Strategies and Preliminary Outcomes
5.2 New Treatment Strategies and Preliminary Outcomes (continued)
5.3 Monoclonal Antibodies Advancing Clinical Trials
5.4 Pharmacological Agents Enhancing Autophagy
5.5 Top Promising Candidates for Alzheimer’s Disease
5.6 Parkinson’s Disease Top Companies
6.1 Neurodegenerative Diseases Market Potential
6.2 Overall Environmental Impact Factors
6.3 Best-fit Industry Partnerships: SWOT Analysis
6.4 Collaborative Framework for Neurodegenerative Diseases
6.5 Overview of Business Partnerships and Technology Capabilities
6.6 Key Aspects to Target through Collaborative Initiatives
7.1 Actionable Impact on Business Development
7.2 Repercussions on Businesses and Processes
7.3 Technology Transfer Assessment
8.1 Alzheimer’s Disease Drug Pipeline
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.1 Alzheimer’s Disease Drug Pipeline (continued)
8.2 Parkinson’s Disease Drug Pipeline
8.2 Parkinson’s Disease Drug Pipeline (continued)
9.1 Key Industry Influencers
9.1 Key Industry Influencers (continued)
9.1 Key Industry Influencers (continued)
9.1 Key Industry Influencers (continued)
9.1 Key Industry Influencers (continued)
Legal Disclaimer
Speak directly with our analytics experts for tailored recommendations.
Recent related Healthcare research
08 Oct 2026 | Global | Frost Radar
Frost Radar: Endoscopy Device Technology Ecosystem, 2026
The endoscopy device market is advancing toward higher-quality visualization and improved clinical decision-making, with innovation across 4K ultrahigh-definition display systems, image-enhanced endoscopy, and computer-aided detection systems. Advanced visualization is evolving through improvements ...
07 Oct 2026 | Global | Technology Research
Growth Opportunities in Image-Guided Cancer Ablation Systems
Image-guided cancer ablation systems are minimally invasive medical technologies that use real-time imaging to accurately guide the placement of an ablation device into a tumor, enabling localized destruction of cancerous tissue while minimizing damage to surrounding healthy structures.The increasin...
06 Oct 2026 | Global | Technology Research
Trends in Laboratory Automation, Global, 2021–2025
This research study provides a comprehensive assessment of the recent trends, technological advancements, and strategic developments shaping the global laboratory automation industry. The analysis traces the evolution of laboratory automation from task-specific automation systems to integrated, inte...
05 Oct 2026 | Global | Frost Radar
Frost Radar™: Point-of-Care Ultrasound Imaging Technology Ecosystem, 2026
The point-of-care ultrasound imaging industry is undergoing a fundamental transformation from equipment-intensive ultrasound to portable, handheld, wireless, AI-enabled, and connected point-of-care solutions. Driven by the need for rapid bedside diagnosis and decentralized healthcare delivery, speci...
25 Sep 2026 | Global | Technology Research
Innovations and Growth Opportunities in Advanced Medical Devices, Diagnostic Solutions, and Implantables
The latest issue of Advanced MedTech Technology Opportunity Engine (TOE) spotlights a diverse slate of innovations across advanced medical devices, diagnostic solutions, and implantables.The issue features advanced medical devices such as peritoneal dialysis fluid system, cold sterilization-based au...
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
| Deliverable Type | Technology Research |
|---|---|
| No Index | No |
| Podcast | No |
| Author | Cecilia Van Cauwenberghe |
| Industries | Healthcare |
| WIP Number | D8BB-01-00-00-00 |
| Is Prebook | No |
Emerging Therapeutics for Neurodegenerative Diseases, Part I: Novel Targeted Therapeutic Strategies Technologies for Alzheimer's and Parkinson's Diseases
$4,950.00
Special Price $3,712.50 save 25 %